Research map: Acquired immune-mediated thrombotic thrombocytopenic purpura with severe cholestatic liver injury and reversible acute kidney injury after ivonescimab-containing chemoimmunotherapy: a case report and literature review

Back to the article

Papers in this map

  1. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance · Filipe Martins · 2019 · 2339 citations · Cited by this paper
  2. A review of soluble mediator and cytokine networks linking combination immunotherapy, tumor microenvironment remodeling and skeletal muscle dysfunction · 2026 · Related
  3. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update · Bryan J. Schneider · 2021 · 2223 citations · Cited by this paper
  4. GFI1 as a novel regulator of γδ T cell development and the IL-17/IFN-γ lineage commitment · 2026 · Related
  5. VEGF Inhibition and Renal Thrombotic Microangiopathy · Vera Eremina · 2008 · 1512 citations · Cited by this paper
  6. HIF-1α-centered metabolic reprogramming in osteoarthritis: cell type-specific effects and intercellular crosstalk among chondrocytes, BMSCs, and macrophages · 2026 · Related
  7. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura · Marie Scully · 2019 · 1042 citations · Cited by this paper
  8. Lipoprotein (a) fuels EV71 replication by activating p38 MAPK-autophagy axis · 2026 · Related
  9. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study · Pavan K. Bendapudi · 2017 · 562 citations · Cited by this paper
  10. Delivery platforms for in vivo CAR-T engineering · 2026 · Related
  11. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura · X. Long Zheng · 2020 · 427 citations · Cited by this paper
  12. Envafolimab – novel anti-PD-1/PD-L1 antibody in cancer treatment · 2026 · Related
  13. Drug-induced thrombotic microangiopathy: a systematic review of published reports · Zayd L. Al‐Nouri · 2014 · 368 citations · Cited by this paper
  14. Integrated plasma proteomics identifies HLA-G and osteopontin as circulating biomarkers of resistance to PD-1 inhibitor plus chemotherapy in choriocarcinoma · 2026 · Related
  15. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura · X. Long Zheng · 2020 · 349 citations · Cited by this paper
  16. Contribution of monocyte subpopulations to the pathogenesis and therapy outcome of type 1 diabetes management in pediatric patients · 2026 · Related
  17. Redefining outcomes in immune TTP: an international working group consensus report · Adam C. Cuker · 2021 · 229 citations · Cited by this paper
  18. Germline based SARS-CoV-2 specific B cell repertoire motif identified with novel sequence based bioinformatic pipeline · 2026 · Related
  19. Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant · HARMONi-A Study Investigators · 2024 · 198 citations · Cited by this paper
  20. Defining nature, responses and drivers of regulatory- and conventional CD4+ T cells in the human term decidua · 2026 · Related
  21. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China · Anwen Xiong · 2025 · 167 citations · Cited by this paper
  22. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura · Wendy Lim · 2015 · 129 citations · Cited by this paper
  23. Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management · Tommaso Mazzierli · 2023 · 84 citations · Cited by this paper
  24. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura · X. Long Zheng · 2025 · 67 citations · Cited by this paper
  25. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP) · Jeanelle King · 2017 · 52 citations · Cited by this paper
  26. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors · Alexey Youssef · 2018 · 39 citations · Cited by this paper
  27. Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy · Moira M. Lancelot · 2020 · 28 citations · Cited by this paper
  28. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system · Donald C. Moore · 2022 · 22 citations · Cited by this paper
  29. Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy · Mansour Gergi · 2020 · 19 citations · Cited by this paper
  30. Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma · William J. Mullally · 2022 · 17 citations · Cited by this paper
  31. Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient With Metastatic Non-Small-Cell Lung Cancer · Samantha De Filippis · 2021 · 16 citations · Cited by this paper
  32. Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab · Derrick C. Nelson · 2022 · 12 citations · Cited by this paper
  33. Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors · T.J.J. Uyl · 2025 · 8 citations · Cited by this paper
  34. Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy · Michael Kozak · 2023 · 5 citations · Cited by this paper
  35. Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer · Yuya Yoshida · 2024 · 5 citations · Cited by this paper
  36. Thrombotic thrombocytopenic purpura as a complication of pembrolizumab: a case report and literature Review · Gregory Palega · 2026 · 2 citations · Cited by this paper
  37. Thrombotic Thrombocytopenic Purpura in a Patient With Triple‐Negative Breast Cancer Treated With PD ‐ L1 Inhibition and Taxane Chemotherapy · Jason Ke · 2026 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)